Chapter 1: Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2: Market Overview
- Genome-Editing Tool Types
- Meganucleases
- Zinc Finger Nucleases
- Transcription Activator-like Effector Nucleases
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
- Gene editing Therapeutics
Chapter 3: Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Increasing Prevalence of Chronic Disease
- Increasing Prevalence of Rare Genetic Disorders
- Precision Medicine
- Increasing Strategic Initiatives
- Market Restraints
- Stringent Regulatory Frameworks and Time-Consuming Approval Processes
- High Cost of Treatment
- Adverse Events and Long-Term Monitoring
- Lack of Skilled Workforce
- Off-Target Impact
- Market Challenges
- Patent Disputes
- Governmental Policies and Regulations
- Ethical Issues
- Market Opportunities
Chapter 4: Emerging Technologies and Developments
- Base Editing
- Prime Editing
- Cas-Clover and Cas-FOKl
- CRISPR Interference and CRISPR Activation
- RNA Editing
- Artificial Intelligence in Genome Editing
Chapter 5: Pipeline Analysis
- Overview
- Clinical Trial Analysis Based on Technology
- Clinical Trial Analysis Based on Diseases
- Designations for Pipeline Drugs
Chapter 7: Market Analysis
- Casgevy
- Market Overview
- Market Analysis
- Market by Region
- North America
- Europe
- Emerging Markets
Chapter 8: Competitive Intelligence
- Strategic Initiatives
- Competitive Landscape
Chapter 9: Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives
- ESG Practices in the Gene Editing Companies
- Concluding Remarks
List of Tables and Figures
Summary Table: Global Market for Gene Editing Therapeutics, Through 2029
Table 1: Comparison of Genome-Editing Tools
Table 2: U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
Table 3: Global Cases and Deaths Due to Various Cancers, 2022
Table 4: Gene Editing Index Ratings, 2020
Table 5: Rating Guide
Table 6: Comparison of Cas9-derived Proteins with Regular SpCas9
Table 7: Gene Editing Therapeutic Trials in Phase I, Till May 2024
Table 8: Gene Editing Therapeutic Trials in Phase I/II, II and III, Till May 2024
Table 9: Casgevy Label Expansion Studies, Till May 2024
Table 10: Examples of Some Pipeline Drugs and Their Designations, as of May 2024
Table 11: Patents on CRISPR Therapeutics, Published in 2021
Table 12: Patents on CRISPR Therapeutics, Published in 2022
Table 13: Patents on CRISPR Therapeutics, Published in 2023
Table 14: Global Market for Gene Editing Therapeutics, Through 2029
Table 15: Global Market for Gene Editing Therapeutics, by Region, Through 2029
Table 16: Strategic Initiatives in the Gene Editing Therapeutics Market, 2020-2024
Table 17: Venture Funding for Startups, 2023
Table 18: ESG Initiatives/Practices by Various Gene Editing Companies, 2023
Table 19: ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
Table 20: Report Information Sources
Table 21: Glossary of Terms Used in This Report
Table 22: Allogene Therapeutics: Company Snapshot
Table 23: Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 24: Allogene Therapeutics: News/Key Developments, 2020-2024
Table 25: Beam Therapeutics: Company Snapshot
Table 26: Beam Therapeutics: Financial Performance, FY 2022 and 2023
Table 27: Beam Therapeutics: News/Key Developments, 2021-2023
Table 28: Caribou Biosciences Inc.: Company Snapshot
Table 29: Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 30: Caribou Biosciences Inc.: News/Key Developments, 2021-2024
Table 31: CRISPR Therapeutics: Company Snapshot
Table 32: CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
Table 33: CRISPR Therapeutics: Product Portfolio
Table 34: CRISPR Therapeutics: News/Key Developments, 2021-2024
Table 35: Editas Medicine: Company Snapshot
Table 36: Editas Medicine: Financial Performance, FY 2022 and 2023
Table 37: Editas Medicine: News/Key Developments, 2022-2024
Table 38: Intellia Therapeutics Inc.: Company Snapshot
Table 39: Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 40: Intellia Therapeutics Inc.: News/Key Developments, 2021-2024
Table 41: Precision Biosciences: Company Snapshot
Table 42: Precision Biosciences: Financial Performance, FY 2022 and 2023
Table 43: Precision Biosciences: News/Key Developments, 2020-2024
Table 44: Sangamo Therapeutics: Company Snapshot
Table 45: Sangamo Therapeutics: Financial Performance, FY 2022 and 2023
Table 46: Sangamo Therapeutics: News/Key Developments, 2024
Table 47: Vertex Pharmaceuticals Inc.: Company Snapshot
Table 48: Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 49: Vertex Pharmaceuticals Inc.: Product Portfolio
Table 50: Vertex Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
Table 51: Verve Therapeutics Inc.: Company Snapshot
Table 52: Verve Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 53: Verve Therapeutics Inc.: News/Key Developments, 2019-2024
Table 54: Vor Bio: Company Snapshot
Table 55: Vor Bio: Financial Performance, FY 2022 and 2023
Table 56: Vor Bio: News/Key Developments, 2020-2024List of Figures
Summary Figure: Global Market for Gene Editing Therapeutics, 2021-2029
Figure 1: Genome-Editing Outcomes
Figure 2: Endonucleases Used in Gene Editing Technologies
Figure 3: Advances in Therapeutic Strategies to Treat Life-Threatening Diseases
Figure 4: CRISPR/Cas9 Therapeutics Timeline, Since 1987-Present
Figure 5: CRISPR/Cas9 Therapeutics Delivery Platform
Figure 6: Delivery Method
Figure 7: Market Dynamics of Gene Editing Therapeutics Market
Figure 8: Genetic Disorders
Figure 9: Emerging Technologies in the Genome-Editing Therapeutics Market
Figure 10: Emerging Therapeutics Applications for RNA Editing by Cas Enzymes
Figure 11: Articles on Gene Editing Therapeutics in PubMed, 2004-2024
Figure 12: Share of Clinical Trials on the Genome-Editing Market, by Technology, Through May 2024
Figure 13: Genome-Editing Clinical Trials, by Diseases
Figure 14: Genome-Editing Clinical Trials, by Trial Phase
Figure 15: Genome-Editing Clinical Trials, by Trial Status
Figure 16: Patents Documented, by Top Owners, 2021-2024
Figure 17: Patents Documented, by Type, 2021-2024
Figure 18: Patents Documented, by Type, 2021-2024
Figure 19: Common Strategies Proposed for the Therapeutic Intervention for ß-thalassemia and Sickle Cell Disease
Figure 20: Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 21: Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 22: Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
